

Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

PD-L1 (E1L3N) XP Rabbit Antibody

RRID:AB_2687655

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 13684, RRID:AB_2687655)

Antibody Information

URL: http://antibodyregistry.org/AB_2687655

Proper Citation: (Cell Signaling Technology Cat# 13684, RRID:AB_2687655)

Target Antigen: PD-L1

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IP, IHC-Bond, IHC-P, FC-FP

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: PD-L1 (E1L3N) XP Rabbit Antibody

Description: This recombinant monoclonal targets PD-L1

Target Organism: human

Clone ID: Clone E1L3N®

Antibody ID: AB_2687655

Vendor: Cell Signaling Technology

Catalog Number: 13684

Record Creation Time: 20260729T221927+0000

Record Last Update: 20260729T221927+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for PD-L1 (E1L3N) XP Rabbit Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 170 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS biology, 24(1), e3003603.

Walsh MJ, et al. (2026) Cellular and molecular profiling of collagenous gastritis implicates pathogenic CD4+ T cells. iScience, 29(1), 114344.

Lou H, et al. (2026) PIK3CA mutant cervical cancer is selectively suppressed by PI3K? inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy. Neoplasia (New York, N.Y.), 76, 101305.

Zhang Z, et al. (2026) Molecular insights into early malignant transition of hepatocellular carcinoma. Cancer cell, 44(5), 1012.

Kawazu M, et al. (2026) Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges. Cancer research communications, 6(4), 961.

Marceaux C, et al. (2026) TNF-?-mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma. Cell reports. Medicine, 7(2), 102593.

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. International immunopharmacology, 178, 116564.

Zhao L, et al. (2026) Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. NPJ precision oncology.

Wu Q, et al. (2026) Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer. *Frontiers in immunology*, 17, 1763068.

Perez KJ, et al. (2026) Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapaneatic Neuroendocrine Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 540.

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. *Cell reports. Medicine*, 7(4), 102704.

Wei S, et al. (2026) A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. *Cell reports. Medicine*, 7(4), 102716.

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. *Nature communications*, 17(1).

Naing A, et al. (2026) Biomarker study of pembrolizumab in patients with advanced rare cancers. *Cell reports. Medicine*, 7(6), 102827.

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. *Cell*.

Hu C, et al. (2026) Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer. *EBioMedicine*, 125, 106154.

van der Elst A, et al. (2026) Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2732.

Lin YC, et al. (2026) SQSTM1/p62-mediated PD-L1 biomolecular condensate formation promotes lung tumorigenesis. *Journal of advanced research*.

Lou H, et al. (2026) A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy. *medRxiv : the preprint server for health sciences*.

Tan M, et al. (2026) A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways. *bioRxiv : the preprint server for biology*.